Claims
- 1. A compound of the Formula (I):
- 2. The compound or salt of claim 1 wherein the compound induces the biosynthesis of one or more cytokines.
- 3. The compound or salt of claim 1 wherein R″ is selected from the group consisting of:
-hydrogen, -alkyl, -alkenyl, -aryl, -heteroaryl, -heterocyclyl, -alkylene-Z-alkyl, -alkylene-Z-aryl, -alkylene-Z-alkenyl, and -alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
—OH, -halogen, —N(R6)2, —C(R7)—N(R6)2, —S(O)2—N(R6)2, —N(R6)—C(R7)—C1-10 alkyl, —N(R6)—S(O)2—C1-10 alkyl, —C(O)—C1-10 alkyl, —C(O)—O—C1-10 alkyl, —N3, -aryl, -heteroaryl, -heterocyclyl, —C(O)-aryl, and —C(O)-heteroaryl; each R6 is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl; each R7 is independently selected from the group consisting of ═O and ═S; and Z is selected from the group consisting of —O— and —S(O)0-2—.
- 4. The compound or salt of claim 1 wherein:
R′″ is R or R3 when n is 1, R or one R and one R3 when n is 2, or R when n is 3 to 4; R is selected from the group consisting of alkyl, alkenyl, alkoxy, halogen, fluoroalkyl, hydroxy, amino, alkylamino, and dialkylamino; R3 is selected from the group consisting of:
-Z′-R4′, -Z′-X′—R4′, -Z′-X′—Y′—R4′, and -Z′-X′—R5′; Z′ is a bond or —O—; X′ is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene, or heterocyclylene and optionally interrupted by one or more —O— groups; Y′ is selected from the group consisting of: 92R4′ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo; R5′ is selected from the group consisting of: 93each R7 is independently selected from the group consisting of ═O and ═S; each R8 is independently C2-7 alkylene; R10 is C3-8 alkylene; each R11 is independently selected from the group consisting of hydrogen, C1-10 alkyl, C2-10 alkenyl, C1-10 alkoxyC2-10 alkylenyl, and arylC1-10 alkylenyl; R12 is selected from the group consisting of hydrogen and alkyl; A′ is selected from the group consisting of —CH2—, —O—, —C(O)—, —S(O)0-2—, and —N(R4′)—; Q is selected from the group consisting of a bond, —C(R7)—, —C(R7)—C(R7)—, —S(O)2—, —C(R7)—N(R11)—W—, —S(O)2—N(R11)—, —C(R7)—O—, and —C(R7)—N(OR12)—; V is selected from the group consisting of —C(R7)—, —O—C(R7)—, —N(R11)—C(R7)—, and —S(O)2—; W is selected from the group consisting of a bond, —C(O)—, and —S(O)2—; and c and d are independently integers from 1 to 6 with the proviso that c+d is ≦7, and when A′ is —O—or —N(R4′)— then c and d are independently integers from 2 to 4.
- 5. A compound of the Formula (II):
- 6. The compound or salt of claim 5 wherein the compound or salt induces the biosynthesis of one or more cytokines.
- 7. A compound of the Formula (I-1):
- 8. The compound or salt according to claim 7 wherein R1 is selected from the group consisting of —R4, —Y—R4, and —X—N(R6)—Y—R4 wherein Y is —C(R7)—, —S(O)2—, or —C(R7)—N(R9)—.
- 9. The compound or salt according to claim 8 wherein R1 is selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkylenyl, arylaikenylenyl, heteroarylalkylenyl, heteroarylalkenylenyl, aminoalkylenyl, alkoxyalkylenyl, acyl, alkylsulfonylaminoalkylenyl, arylsulfonylaminoalkylenyl, alkylaminocarbonyl, arylaminocarbonyl, (arylalkylenyl)aminoalkylenyl, heterocyclylcarbonylaminoalkylenyl, and arylaminocarbonylaminoalkylenyl.
- 10. The compound or salt according to claim 9 wherein R1 is selected from the group consisting of hydrogen, methyl, isopropyl, butyl, 2-methylpropyl, 1-ethylpropyl, 3-methylbutyl, cyclohexyl, benzyl, 3-phenylpropyl, cinnamyl, furan-2-ylmethyl, and —CH2CH2CH2—NHR13, wherein R13 is selected from the group consisting of methanesulfonyl, phenylsulfonyl, benzyl, isopropylaminocarbonyl, morpholine-4-carbonyl, and phenylaminocarbonyl.
- 11. The compound or salt according to claim 7 wherein R1′ is hydrogen.
- 12. The compound or salt of claim 7 wherein R1 and R1′ are each independently alkyl.
- 13. The compound or salt of claim 7 wherein R1 and R1′ join to form the group:
- 14. The compound or salt according to claim 7 wherein R2 is selected from the group consisting of hydrogen, alkyl, and alkoxyalkylenyl.
- 15. The compound or salt according to claim 14 wherein R2 is selected from the group consisting of hydrogen, methyl, propyl, butyl, 2-methoxyethyl, and ethoxymethyl.
- 16. The compound or salt according to claim 7 wherein n is 0.
- 17. The compound or salt according to claim 7 wherein n is 0, and R3 is selected from the group consisting of -Z′-R4′, -Z′-X′—R4′, and -Z′-X′—Y′—R4′.
- 18. The compound or salt according to claim 17 wherein R3 is selected from the group consisting of 2-(pyridin-3-yl)ethyl, pyridinyl, hydroxymethylpyridinyl, ethoxyphenyl, (morpholine-4-carbonyl)phenyl, 2-(methanesulfonylamino)ethoxy, and benzyloxy.
- 19. A compound of the Formula (I-2):
- 20. The compound or salt according to claim 19 wherein R1 is selected from the group consisting of —R4, —Y—R4, and —X—N(R6)—Y—R4 wherein Y is —C(R7)—, —S(O)2—, or —C(R7)—N(R9)—.
- 21. The compound or salt according to claim 20 wherein R1 is selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkylenyl, arylalkenylenyl, heteroarylalkylenyl, heteroarylalkenylenyl, aminoalkylenyl, alkoxyalkylenyl, acyl, alkylsulfonylaminoalkylenyl, arylsulfonylaminoalkylenyl, alkylaminocarbonyl, arylaminocarbonyl, (arylalkylenyl)aminoalkylenyl, and arylaminocarbonylaminoalkylenyl.
- 22. The compound or salt according to claim 21 wherein R1 is selected from the group consisting of hydrogen, methyl, isopropyl, butyl, 2-methylpropyl, 1-ethylpropyl, 3-methylbutyl, cyclohexyl, benzyl, cinnamyl, furan-2-ylmethyl, and —CH2CH2CH2—NHR13, wherein R13 is selected from the group consisting of methanesulfonyl, phenylsulfonyl, benzyl, and phenylaminocarbonyl.
- 23. The compound or salt according to claim 19 wherein R1′ is hydrogen.
- 24. The compound or salt of claim 19 wherein R1 and R1′ are each independently alkyl.
- 25. The compound or salt of claim 19 wherein R1 and R1′ join to form the group:
- 26. The compound or salt according to claim 19 wherein R2 is selected from the group consisting of hydrogen, alkyl, and alkoxyalkylenyl.
- 27. The compound or salt according to claim 26 wherein R2 is selected from the group consisting of hydrogen, butyl, 2-methoxyethyl, and ethoxymethyl.
- 28. The compound or salt according to claim 19 wherein n is 0.
- 29. The compound or salt according to claim 19 wherein n is 1, and R is halogen or hydroxy.
- 30. A compound of the Formula (I-3):
- 31. The compound or salt according to claim 30 wherein R1 is selected from —R4, —Y—R4, and —X—N(R6)—Y—R4 wherein Y is —CR7—, —SO2—, or —CR7—N(R9)—.
- 32. The compound or salt according to claim 31 wherein R1 is selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkylenyl, arylalkenylenyl, heteroarylalkylenyl, heteroarylalkenylenyl, aminoalkylenyl, alkoxyalkylenyl, acyl, alkylsulfonylaminoalkylenyl, arylsulfonylaminoalkylenyl, alkylaminocarbonyl, arylaminocarbonyl, (arylalkylenyl)aminoalkylenyl, and arylaminocarbonylaminoalkylenyl.
- 33. The compound or salt according to claim 32 wherein R1 is selected from hydrogen, isopropyl, butyl, cyclohexyl, benzyl, cinnamyl, and —CH2CH2CH2—NHR13, wherein R13 is selected from methanesulfonyl, phenylsulfonyl, benzyl, and phenylaminocarbonyl.
- 34. The compound or salt according to claim 30 wherein R1′ is hydrogen.
- 35. The compound or salt according to claim 30 wherein R2A is selected from hydrogen, alkyl, and alkoxyalkylenyl.
- 36. The compound or salt according to claim 35 wherein R2A is selected from hydrogen, butyl, methoxyethyl, and ethoxymethyl.
- 37. The compound or salt according to claim 30 wherein n is 0.
- 38. A compound of the Formula (II-1):
- 39. The compound or salt according to claim 38 wherein R1 is selected from the group consisting of —R4, —Y—R4, and —X—N(R6)—Y—R4 wherein Y is —C(R7)—, —S(O)2—, or —C(R7)—N(R9)—.
- 40. The compound or salt according to claim 39 wherein R1 is selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkylenyl, arylalkenylenyl, heteroarylalkylenyl, heteroarylalkenylenyl, aminoalkylenyl, alkoxyalkylenyl, acyl, alkylsulfonylaminoalkylenyl, arylsulfonylaminoalkylenyl, alkylaminocarbonyl, arylaminocarbonyl, (arylalkylenyl)aminoalkylenyl, and arylaminocarbonylaminoalkylenyl.
- 41. The compound or salt according to claim 39 wherein R1 is selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkylenyl, arylalkenylenyl, heteroarylalkylenyl, heteroarylalkenylenyl, aminoalkylenyl, alkoxyalkylenyl, acyl, alkylsulfonylaminoalkylenyl, arylsulfonylaminoalkylenyl, alkylaminocarbonyl, arylaminocarbonyl, (arylalkylenyl)aminoalkylenyl, heterocyclylcarbonylaminoalkylenyl, and arylaminocarbonylaminoalkylenyl.
- 42. The compound or salt according to claim 40 wherein R1 is selected from the group consisting of hydrogen, methyl, isopropyl, butyl, 2-methylpropyl, 1-ethylpropyl, 3-methylbutyl, cyclohexyl, benzyl, cinnamyl, furan-2-ylmethyl, and —CH2CH2CH2—NHR13, wherein R13 is selected from the group consisting of methanesulfonyl, phenylsulfonyl, benzyl, and phenylaminocarbonyl.
- 43. The compound or salt according to claim 41 wherein R1 is selected from the group consisting of hydrogen, methyl, isopropyl, butyl, 2-methylpropyl, 1-ethylpropyl, 3-methylbutyl, cyclohexyl, benzyl, 3-phenylpropyl, cinnamyl, furan-2-ylmethyl, and —CH2CH2CH2—NHR13, wherein R13 is selected from the group consisting of methanesulfonyl, phenylsulfonyl, benzyl, isopropylaminocarbonyl, morpholine-4-carbonyl, and phenylaminocarbonyl.
- 44. The compound or salt according to claim 38 wherein R1′ is hydrogen.
- 45. The compound or salt of claim 38 wherein R1 and R1′ are each independently alkyl.
- 46. The compound or salt of claim 38 wherein R1 and R1′ join to form the group:
- 47. The compound or salt according to claim 38 wherein R2 is selected from the group consisting of hydrogen, alkyl, and alkoxyalkylenyl.
- 48. The compound or salt according to claim 47 wherein R2 is selected from the group consisting of hydrogen, butyl, 2-methoxyethyl, and ethoxymethyl.
- 49. The compound or salt according to claim 47 wherein R2 is selected from the group consisting of hydrogen, methyl, propyl, butyl, 2-methoxyethyl, and ethoxymethyl.
- 50. The compound or salt according to claim 38 wherein n is 0.
- 51. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 and a pharmaceutically acceptable carrier.
- 52. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 5 and a pharmaceutically acceptable carrier.
- 53. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 7 and a pharmaceutically acceptable carrier.
- 54. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 19 and a pharmaceutically acceptable carrier.
- 55. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 30 and a pharmaceutically acceptable carrier.
- 56. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 38 and a pharmaceutically acceptable carrier.
- 57. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 1 to the animal.
- 58. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 5 to the animal.
- 59. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 7 to the animal.
- 60. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 19 to the animal.
- 61. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 30 to the animal.
- 62. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 38 to the animal.
- 63. A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 1.
- 64. A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 5.
- 65. A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 7.
- 66. A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 19.
- 67. A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 30.
- 68. A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 38.
- 69. A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 1.
- 70. A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 5.
- 71. A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 7.
- 72. A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 19.
- 73. A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 30.
- 74. A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 38.
- 75. A compound of the Formula (VII):
- 76. A compound of the Formula (IX):
- 77. A compound of the Formula (X):
- 78. A compound of the Formula (XLII):
- 79. A compound of the Formula (XLIII):
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims priority to U.S. Provisional Application No. 60/453,128, filed Mar. 7, 2003, and to U.S. Provisional Application No. 60/532,191, filed Dec. 23, 2003, which are both incorporated herein by reference in their entirety.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60453128 |
Mar 2003 |
US |
|
60532191 |
Dec 2003 |
US |